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ABSTRACT 
Introduction 
Multiple myeloma (MM) is an incurable disease characterized by clonal plasma cell proliferation and 
overproduction of monoclonal paraprotein, hypercalcemia, renal failure, anemia, osteolytic bone lesions, and 
infections.  
Melphalan, a nitrogen mustard, is an alkylating agent synthesized in 1953, and it has been used in multiple 
myeloma therapy for fifty years.  Although novel agents have been introduced in the past few decades 
improving prognosis of the disease, melphalan still maintains a crucial role in the treatment of MM acting 
both as cytotoxic agent through damage to DNA, and as immunostimulatory drug by inhibiting Interleukin-6, 
as well as interaction with dendritic cells, and immunogenic effects in tumor microenvironment.  
Areas covered 
This review focuses on available data about melphalan pharmacology and its role in clinical practice.  
Expert opinion 
Melphalan remains crucial in therapy of multiple myeloma because of its good manageability, safety profile, 
efficacy, and economic sustainability. These characteristics make it pivotal also for new regimens in 
combination with novel agents. 
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1. INTRODUCTION 
Multiple myeloma (MM) is a B-cell malignancy characterized by clonal plasma cell proliferation and over 
production of monoclonal paraprotein;1,2 it accounts for >10% of hematologic malignancies and ≈1% of all 
cancers. Typical disease manifestations are: hypercalcemia,  renal failure, anemia, osteolytic bone lesions, 
and infections.3   
Nowadays, therapeutic strategy is based on patient’s eligibility to autologous stem cell transplantation 
(ASCT): younger (<65 years), fit patients undergo high-dose therapy (HDT) followed by ASCT, whereas 
elderly (≥65 years) or unfit patients are treated with conventional chemotherapy . 
During the past two decades, the introduction of proteasome inhibitors (PIs), immunomodulatory drugs 
(IMiDs), and monoclonal antibodies (MoAbs) doubled life expectancy in MM patients.4 However, MM 
remains incurable, with several relapses, and progressively shorter disease free survival (DFS). Therefore, 
further research to find novel effective drugs is needed. However, the development and administration of 
new, highly selective, therapeutic agents are associated with elevated economic costs5 and not always with a 
real clinical benefit, due to the high heterogeneity in pathophysiology of MM cells.6 In this complex scenario 
alkylating agents, such as melphalan, still maintain a role, because of proved clinical safety/efficacy and 
reduced costs. 
2. OVERVIEW OF THE MARKET 
Currently, melphalan (Alkeran®) is approved by Food and Drug Administration (FDA) and European 
Medicine Agency (EMA) for the treatment of MM and other hematological and solid cancers. In MM, 
melphalan is administered either intravenously at the dose of 200 mg/m2 (HDM) followed by ASCT in 
transplant-eligible patients; or orally, in combination with prednisone at various dosages, and usually 
combined with PIs (such as bortezomib) or IMiDs (such as  thalidomide), both in newly diagnosed (ND) and 
relapsed/refractory (RR) patients, unsuitable for ASCT.  
In 2015, melflufen, an alkylating agent consisting of melphalan combined to flufenamide, was approved as 
orphan drug by both FDA and EMA for the treatment of  relapsed/refractory MM.7  
In 2016, EVOMELATM, propylene glycol-free melphalan was approved by FDA. This formulation 
incorporates a modified cyclodextrin, Captisol, that increases the solubility and stability of melphalan and 
provides a safer method of administration.8,9  
3. MELPHALAN 
3.1. Introduction to the compound 
Melphalan, also called L-phenylalanine mustard (L-PAM) or L-sarcolysin, is a phenylalanine derivative of 
nitrogen mustard with a bifunctional alkylating activity. 
Alkeran® is available both orally, in film-coated tablet form containing 2 mg of melphalan, or for 
intravenous injection, supplied as a sterile, non-pyrogenic, freeze-dried powder. Each single-use vial contains 
melphalan hydrochloride equivalent to 50 mg melphalan and povidone.8 
 
3.2. Chemistry 
Melphalan, also known as 4-[bis(2-chloroethyl)amino]-L-phenylalanine or (2S)-2-amino-3-[4-[bis(2-
chloroethyl)amino]phenyl]propanoic acid, was synthesized in 1953, substituting the aminoacid 
phenylalanine for the methyl group on nitrogen mustard.10 The active L-isomer melphalan was preferred for 
development because the D-isomer was less active against certain animal tumors. Melphalan is almost 
insoluble in water, soluble in ethanol and propylene glycol, and it has a pKa1 of ∼2.5. The molecular 
formula is C13H18Cl2N2O2 and the molecular weight is 305.20 (Drug summary).8,11 
 
3.3. Pharmacodynamics 
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Melphalan, as all nitrogen mustards, acts as non-specific DNA alkylating agent creating bifunctional adducts 
with cross-links in DNA. These covalent bindings deform the double helix of DNA and are responsible for 
the cytotoxic action interfering with the polymerases function. Moreover, these adducts can carry out 
deletions, strand scissions and the formation of open rings leading to cell apoptosis.12   
Since phenylalanine is an intrinsic part of its structure, melphalan is actively transported into cells by the 
high-affinity L-amino acid transport system.13 Once melphalan gets into intracellular environment, it forms 
inter-strand or intra-strand DNA cross-links or DNA-protein cross-links by the two chlorethyl groups of the 
molecule (alkylation). In aqueous solutions, the chlorethyl group can spontaneously lose the chloride ion, 
leading to a positively charged and highly reactive cation (aziridinium) able to react with negatively charged, 
electron-rich nucleophilic sites on biologic molecules.14 The N7 position of guanine is the only biologically 
relevant attack site, because the other purine basic nitrogen sites are structurally inaccessible to aziridinium 
(Figure 2).15  
 
Reparative events of DNA covalent crosslinks are considered a mechanism of clinical resistance to the 
drug.16 Although alkylation is the main mechanism of action, melphalan also inhibits malignant cell growth 
through the deepest reduction in Interleukin-6 (IL-6) protein expression compared with several other 
chemotherapeutic agents. Indeed, IL-6 is secreted by bone marrow stromal cells and osteoblasts, and it is one 
of the major cytokines involved in survival and proliferation of myeloma cells through the binding of IL-6-
Receptor-α, particularly highly expressed in MM cells.17,18 Moreover, melphalan treatment could create an 
inflammatory milieu, able to activate an immune response against neoplastic cells.19  Indeed, calreticulin 
(CRT) surfacing from endoplasmic reticulum (ER) of MM cells represents an “eat-me” signal for dendritic 
cells (DCs). Furthermore, the high-mobility group box 1 (HMGB1), released by dying tumor cells, could act 
upon Toll-like Receptor 4 (TLR4) on DCs, and finally, adenosine triphosphate (ATP) released by dying 
malignant cells can trigger purinergic P2RX7 receptors on DCs inducing the production of pro-inflammatory 
cytokine IL-1β through the activation of NLRP3 inflammasome.20  
 
3.4. Pharmacokinetics and metabolism 
The pharmacokinetic behavior of melphalan is difficult to determine because the drug undergoes 
spontaneous hydrolysis in aqueous media, is extensively bound to plasma proteins, and is not significantly 
metabolized.21   
 
3.4.1. Absorption and distribution 
Studies of HDM administered orally confirmed that absorption is variable between patients, showing 
remarkable inter-patient differences in pharmacokinetic parameters with respect to both the time to first 
appearance of the drug in plasma (range: 0-6 hours) and peak plasma concentration (Cmax). The average 
absolute bioavailability of melphalan is also highly variable (range: 56-93%).8   
Since the elimination half-life (t1/2β) and the time to peak plasma level are similar, the variability in 
absorption may be due to effects of prior doses and/or other chemotherapeutic agents on the intestinal 
mucosa, or to saturation of the energy-dependent amino acid transport system used by melphalan because of 
the high doses.22 
There is some evidence of a saturable mechanism for melphalan absorption. Since there is no appreciable 
active metabolism in vivo, it is possible that the increase in peak plasma level and area under the 
concentration/time curve (AUC) might be due to changes in drug transport.23 In addition, absorption may be 
affected by food intake with a median reduction of AUC of 39% and a reduction in bioavailability from 85% 
to 58% when oral melphalan is administered after a meal.24 
After intravenous administration, melphalan rapidly disappears from the plasma and is distributed in whole 
body water (Vd = 0.66 L/kg).25 In several studies, the distribution of melphalan shows a biphasic, open, two-
compartment model. The distribution half-life (t1/2α) is short, ranging between 5 and 15 minutes, and 
proportions of the t1/2β vary five-fold, ranging from 17 to 75 minutes at doses of 140-180 mg/m2. The short 
half-life of HDM allows for the reinfusion of hematopoietic stem cells within 8 to 24 hours by melphalan 
administration.14 
 
3.4.2. Metabolism and excretion 
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Several studies have shown that spontaneous degradation is the primary route for melphalan elimination. The 
compound seems to be rapidly hydrolyzed in plasma. Almost 90% of drug is bound to plasma proteins. 
Serum albumin is the major binding protein, accounting for 40-60% of the plasma protein binding, while α1-
acid glycoprotein accounts for another 20%. Melphalan is eliminated from plasma primarily by chemical 
hydrolysis to the non-cytotoxic monohydroxy- and dihydroxy- metabolites.25 
The small amount of compound observed in urine suggests that renal function is not important in the 
excretion of intravenously administered melphalan. However, an increase in non-hematological toxicity and 
mortality has been reported when HDM was administered in MM patients with renal failure.26,27 Therefore, 
in clinical practice both oral and intravenous melphalan dose reductions, based on glomerular filtration rates, 
are recommended.28–30 
Drug interactions with melphalan are unknown since degradation does not involve hepatic metabolism. 
4. CLINICAL EFFICACY 
The first report of melphalan in anti-myeloma therapy dates back to 1958 by Blokhin et al, who treated 6 
patients and obtained a considerable reduction in the tumor size in 3 of them.31 Since then, melphalan 
therapeutic utilization evolved along two parallel lines: oral administration in combination with steroids and 
high-dose intravenous infusion as preparative regimen for autologous transplantation. Additionally, a 
melphalan derivative prodrug, melflufen, has been recently developed and is under clinical evaluation. 
4.1 Oral melphalan 
The oral combination of melphalan and prednisone (MP) against MM was first described by Alexanian et al 
in 1969.32 In clinical trials, MP showed an overall response rate (ORR) of 35-55% with a median survival of 
2-3 years. Subsequently it was introduced as standard treatment for elderly MM  patients,33 and was 
considered the reference approach for more than 30 years.34  
A data review of 27 randomized clinical trials carried out by The Myeloma Trialists’ Collaborative Group in 
1998 found no difference in terms of survival between MP and melphalan in combination with procarbazine,  
carmustine, cyclophosphamide, methyl-CCNU, vincristine, doxorubicin, peptichemio, or dexamethasone.35 
Recently, the introduction of IMiDs, such as thalidomide or lenalidomide, and the PI bortezomib, has 
changed the treatment paradigm of MM and extended survival. A number of phase 3 trials have demonstrated 
the efficacy of novel agent combinations including MP as backbone for the treatment of elderly NDMM 
patients. 
Six randomized studies  showed superiority of MP-thalidomide (MPT) combination vs standard MP: higher 
responses translated into a longer progression-free survival (PFS).  However, the effect on overall survival 
(OS) varied across trials.36–42 A meta-analysis of these studies, including 1685 patients, integrated the 
existing efficacy data and showed a 5-month increase in median PFS and also a 6-month longer median 
overall survival (OS) in favor of MPT (Table 1).43 
 
The phase 3, randomized, multicenter, VISTA trial, randomly assigned 682 patients to receive nine 6-week 
cycles of melphalan (at a dose of 9 mg/m2) and prednisone (at a dose of 60 mg/m2) on days 1 to 4, either 
alone or with bortezomib (VMP) at a dose of 1.3 mg/m2 on days 1, 4, 8, 11, 22, 25, 29, and 32 during cycles 
1 to 4 and on days 1, 8, 22, and 29 during cycles 5 to 9. ORR in bortezomib group almost doubled the MP 
control group (74 vs 39%, P<0.001), and median progression-free survival (PFS) significantly differed in 
favor of bortezomib group (22 vs 15 months, P<0.001).44 The median overall survival (OS) was not reached 
in the VMP arm vs 43 months in the MP group, and hazard ratio (HR) also favored the bortezomib-
containing group (HR 0.653, P <0.001) (Table 1).45 
The MM-015 trial was a double-blind phase 3 trial in which 459 patients were randomly assigned to receive 
MP alone, or in combination with lenalidomide (MPR) with or without lenalidomide maintenance (MPR-R). 
Primary endpoint was PFS and MPR-R resulted superior than MPR and MP (31 vs 14 vs 13 months, 
respectively). The major benefit  on PFS was associated with lenalidomide maintenance therapy. Also ORR 
was higher in MPR-R group (77% vs 68% vs 50%, respectively). Median 3-years OS did not differ 
significantly (Table 1).46  
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In a subsequent phase 3 trial, MPT was compared to MPR but not significant differences were showed in 
ORRs, PFS, or OS (Table 1).47  
More recently,  results of a phase 3 trial, comparing fixed duration of carfilzomib plus MP (KMP) vs VMP 
for 9 induction cycles were presented.48 The primary endpoint of KMP superiority in median PFS was not 
met (22 months for both KMP and VMP, HR 0.91, 95% CI, 0.75 - 1.10). The ORR was 84% with KMP vs 
79% with VMP. The HR for OS (KMP versus VMP) was 1.21 (95% CI, 0.90 - 1.64)49 (Table 1). 
 
4.2 High-dose intravenous melphalan 
The earliest attempts of HDT with melphalan 80-140 mg/m2 infusion were not followed by ASCT.50–56 
Barlogie et al found that the myelotoxicity of HDM was reduced in patients who underwent  ASCT.57,58 
Various trials were performed to compare HDT-ASCT with conventional chemotherapy, but only two of 
them, conducted by Attal and Child et al, provided strong evidence for survival benefit (Table 2).59–64 
The superiority of HDT-ASCT as upfront approach in NDMM patients ≤65 years of age, also in comparison 
to chemotherapeutic regimens incorporating novel agents, such as lenalidomide and bortezomib, has been 
recently confirmed (Table 2).65–67   
Melphalan 200 mg/m2 is the optimal myelo-preparative conditioning regimen for ASCT in MM . Higher 
doses, or association with total body irradiation (TBI) or with other chemotherapeutic drugs, such as 
busulfan, failed to improve efficacy and worsened toxicity profile.68–70 On the other side, dose reductions, 
despite being associated with a better safety profile, showed lower efficacy, and should be considered only 
in patients with comorbidities or at higher risk for transplant-related complications.39,71 
   
4.3 Melflufen  
Melflufen is a novel melphalan containing prodrug with Flufenamide that enables the agent to easily get into 
cells. . 
Preclinical in vitro and in vivo studies  showed higher anti-MM activity compared to melphalan, as well as 
synergistic effects in combination with bortezomib, lenalidomide or dexamethasone.72–75  
NCT01897714 is an ongoing Phase 1/2a study evaluating melflufen in combination with dexamethasone for 
RRMM patients. The maximum tolerated dose (MTD) of melflufen was determined to be 40 mg 
intravenously every 3 weeks in combination with low-dose dexamethasone. In 23 patients evaluable for 
response, the ORR was 48%.76,77. 
 
 
4.4 Evomela 
The new formulation of melphalan with Captisol EVOMELA,9 was tested in in MM patients undergoing 
ASCT. It was administered as 2 doses of 100 mg/m2 in 61 patients. The ORR reported prior of ASCT was 
79% and increased to 100% after ASCT with a CR rate of 21%.78   
 
5. POST MARKETING SURVEILLANCE 
The Regulatory Authorities (RA) have developed  post marketing surveillance programs to monitor the 
safety profile of new marketed drugs.7,79–81 FDA has introduced the use of black boxed warnings to advise 
users on the risk of serious adverse drug reactions (ADRs).82 Recently, an analysis of boxed warnings issued 
for all MM drugs highlighted that, after melphalan approval in 1964, four different warning revisions have 
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been published (Table 3).83 A significant change in reporting rates for melphalan-associated leukemia, bone 
marrow suppression and chromosomal aberrations has been detected after the introduction of boxed 
warnings.84 The notification of ADRs to the FDA Adverse Event Reporting System (FAERS)79,80 increased 
the statistical association measured with the Empirical Bayes Geometric Mean (EBGM)  for melphalan-
associated bone marrow suppression and chromosomal aberrations (Table 3). 
A Japanese study reviewed the reports submitted to FAERS to assess taste dysfunction induced by the 
administration of MM drugs, covering the period from 1997 to 2014.85 Signals were detected via quantitative 
data mining algorithms specific for the terms: ageusia, dysgeusia and hypogeusia. The highest signal score 
related to melphalan was associated to hypogeusia.  
 
6. SAFETY and TOLERABILITY 
6.1 Oral melphalan 
MP showed good safety profile: grade (G) ≥3 hematological toxicities were about 15%, whereas G≥3 non-
hematological adverse events (AEs) were rare (<5%), and the majority of them were infections.86,87 
MPT combination was associated with higher toxicity compared with MP: the six randomized studies  
included in the meta-analysis by Fayer et al  showed that AE rates in MPT arm were almost double as 
compared with MP, and the most frequent ones were polyneuropathy, constipation, infections, thrombosis, 
and exanthema. 36–43  As for VMP combination, peripheral sensory neuropathy, G≥3 gastrointestinal AEs, and 
incidence of Herpes Zoster were more frequent in bortezomib group, whereas VMP and MP did not differ 
significantly in death rates during treatment (5% and 4%, respectively) or treatment-related death (1% and 
2%).44 
 
MPR showed similar overall toxicity profile compared to MPT; indeed, despite a significant reduction in 
G≥2 neuropathy (44% in MPT vs 8% in MPR, P <0 .001), G≥3 hematologic AEs were significantly more 
frequent in the lenalidomide group (anemia: 14% vs 5%; thrombocytopenia: 30% vs 8%; neutropenia: 64% 
vs 27%; all P <0.001), whereas the incidence of G≥2 venous thrombotic events was 8% in both arms.47 
In the KMP vs VMP trial, rates of G≥3 hypertension, dyspnea, acute renal failure, and cardiac failure were 
higher in the carfilzomib group compared to the bortezomib one. 
6.2 High-dose intravenous melphalan 
HDM without ASCT led to 8-20% of mortality rate, usually for sepsis, and the median duration of 
neutropenia and thrombocytopenia was 24-30 and 28-36 days, respectively.51–56,88 The introduction of 
autologous transplant and G-CSF support significantly reduced myelotoxicity,56 and advances in support-
therapy strongly reduced mortality rate (<2%).56,57,67,89 In the last phase 3, multicenter, randomized clinical 
trial in which HDM was compared to novel agents other frequent AEs related to HDM included infections 
(20%), mucositis (17%), nausea and vomiting (7%), diarrhea (4%), fatigue (2%),.67,89 
To prevent mucositis, amifostine administration prior to HDM showed some utility in clinical trials.90,91 
At diagnosis, 15-40% of patients with MM have renal impairment. Although melphalan clearance is renal 
function-dependent, pharmacokinetic studies showed large inter-individual variations in pharmacokinetic 
parameters.92 For these reasons, melphalan optimal dosing in patients with renal clearance <60 ml/min is a 
controversial topic. Although a recent retrospective study seems to suggest improved response and longer 
treatment-free survival in patients with renal clearance <60 ml/min treated with melphalan 200 mg/m2,93 a 
Consensus Statement on behalf of the International Myeloma Working Group, and the European Myeloma 
Network Guidelines for the management of MM related complications recommends to reduce melphalan 
dose to 140 mg/m2 in case of renal clearance <60 ml/min.92,94 
     
 
      6.3 Melflufen 
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Melflufen, in phase 2a trial, was associated mostly with hematologic toxicities (thrombocytopenia: 68%, 
neutropenia: 55%, anemia: 42%, leukopenia: 32%)76. 
6.4 Evomela  
Safety profile of EVOMELA was shown to be consistent with the established side effect profile of high-dose 
i.v. melphalan.with a a lower rate of mucositis compared (12% to 43%).78  
 
7. REGULATORY AFFAIRS 
Since melphalan approval in 1964, the standard melphalan formulation used for MM treatment is Alkeran®,a 
registered trademark of GlaxoSmithKline. Tablet formulation was reviewed by FDA on 24th  May 2001. On 
1st July 2002, FDA approved Alkeran® (melphalan hydrochloride) for injection. On 22nd  March 2017,95,96 
FDA approved the first bioequivalent of oral Alkeran®, produced by Alvogen Malta. Six different 
bioequivalent drugs of Alkeran® for injection have been approved since 2009.97  
In March 2015, a prodrug of melphalan currently evaluated in a phase 1/2a trial, Melflufen, received the 
Orphan Drug Designation from both FDA and EMA98 
A new formulation for injection was approved on 3rd October 2016, called EVOMELATM(Captisol®-enabled 
melphalan HCl). It has two indications in MM patients: HDT prior to ASCT and palliative treatment.99,100  
.   
 
8. CONCLUSION 
After fifty years of use, the alkylating agent melphalan still maintains a crucial role in MM therapy. In 
younger, fit patients intravenous HDM is used as preparative regimen for ASCT, whereas in elderly patients 
oral melphalan is used in combination regimens with PIs, IMiDs, MoAbs and/or prednisone. Oral melphalan, 
thanks to its limited toxicity and easy management, has also a palliative function in frail patients. 
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9. EXPERT OPINION  
In MM there is growing need for therapeutic strategies that could prolong the survival of patients as much as 
possible. Indeed, despite the recent advances with novel effective agents, MM patients eventually relapse. In 
particular, the disease is characterized by multiple relapses, development of drug-resistance, and decreasing 
DFS, therefore newer agents to be used in subsequent lines of therapy are needed.  
Although several novel agents have been introduced in the past few years, regulatory and/or economic issues 
may be a limitation to their use and could reduce their availability.   
In the pharmaco-economic context, when analyzing the economic issues associated with the use of new 
drugs,  three different and highly relevant aspects should be taken into account. First, survival of MM 
patients has considerably increased (to more than 10 years) in the last fifteen years, thus patients receive 
effective – and also quite expensive – treatments for a prolonged time. Second, combo-therapy, that is the 
association of synergistic and highly effective novel agents, has become a common and valid practice, 
therefore treatments include more than one effective – and again expensive – agents. Third, continuous 
therapy has become a widely accepted strategy, and most of trials in fact incorporate a maintenance treatment 
for at least two years or until relapse/intolerance, thus prolonging the time on treatment. All these factors, 
despite showing the impressive steps forward thanks to the clinical research, have dramatically increased the 
economic burden to national health systems.     
In more detail, patients who receive induction, transplantation and maintenance, cost about 100.000$ per 
year.5 The introduction of novel agents increase costs to 300.000$ per year.101 Recently, Niphadkar et al 
compared cost between novel agents and ASCT. The study showed that induction with lenalidomide and 
dexamethasone, followed by ASCT and lenalidomide maintenance is efficacious for the treatment of newly 
diagnosed MM, and the cost associated with the induction and transplant represents only 22% of the total 
cost, whereas lenalidomide maintenance makes up 78%. Moreover, the study showed that most of the novel 
agents used in combination regimens are more expensive than ASCT, despite non clear data of significant 
superiority in terms of efficacy..102  
Melphalan, approved in 1964, is a well-known alkylating agent that is still pivotal in MM therapy, due to its 
demonstrated efficacy, good safety profile, and limited costs thanks to several bioequivalent drugs already 
marketed. Moreover, oncologists and hematologists have been using this drug for about 50 years in clinical 
practice, which makes them quite confident with melphalan administration. The good manageability of this 
alkylating agent is confirmed by the fact that HDM followed by ASCT in accurately selected American and 
Canadian patients is safely performed also in outpatient setting, with great patient satisfaction.103  
Of note, because of its versatility, melphalan can be easily combined with novel agents, enhancing their 
efficacy. 
Topicality of melphalan is reinforced by the new discoveries of its prodrug melflufen and the new 
formulation EVOMELA. Melflufen showed ORRs of ≈40% in heavily pre-treated, pluri-refractory MM 
patients. This was possible thanks to both the intrinsic property of melflufen to reach higher concentration in 
MM cells than its parental drug, and because of its mechanism of action capable to overcome heterogeneity 
in neoplastic clones. EVOMELA combines the Captisol technology, also used in 6 other drugs approved by 
FDA (Vfen, Nexterone, Geodon, Abifily, Kyprolis and Noxaifl). This formulation avoids the use of 
propylene glycol than can contribute to the onset of metabolic and renal dysfunction mainly. Results showed 
the bioequivalence of the two melphalan formulations, with consistent safety and efficacy profile of 
conventional melphalan formulation.78  
In conclusion, melphalan in MM therapy remains crucial because of its easy-management, safety, efficacy 
profile, and economic sustainability. These characteristics make it pivotal also for new regimens in 
combination with novel agents. 
 
11 
Declaration of Interest: Mario Boccadoro has received honoraria from Sanofi, Celgene, Amgen, Janssen, 
Novartis, Abbivie, BMS; research funding from Celgene, Janssen, Amgen, BMS, Mundipharma, Novartis, 
Sanofi; Alessandra Larocca has received honoraria from Amgen, BMS, Celgene and Janssen-Cilag. The other 
authors have no conflicts of interest 
 
 
Figure Legend. 
Figure 1. Melphalan alkylating mechanism 
 
Figure 1. 
 
 
 
The chloroethylamine moiety forms an aziridinium cation which reacts with DNA bases such as N7 position of guanine, 
producing an alkylated purine. The alkylation of a second guanine residue leads to cross-linking of DNA strands 
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Table 1: efficacy results of phase 3, randomized, multicenter clinical trials combining novel agents to melphalan and prednisone as upfront therapy in MM 
patients ineligible for autologous transplantation. 
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Legend: y: years; ORR: overall response rate (≥PR); PR: partial response; PFS: progression-free survival; m: months; OS: overall survival; Mel: melphalan per 
os; NA: novel agent; CG: control group; NDMM: newly diagnosed multiple myeloma; ASCT: autologous stem cell transplantation; MPT: melphalan, prednisone, 
thalidomide; MP: melphalan, prednisone; r: range; VMP: bortezomib, melphalan, prednisone; CR: complete response; NR: not reached; MPR: melphalan, 
prednisone, lenalidomide; MPR-R: melphalan, prednisone, lenalidomide, followed by lenalidomide maintenance; MPT-T: melphalan, prednisone, thalidomide, 
followed by thalidomide maintenance; †: results not significantly different;  KMP: carfilzomib, melphalan, prednisone; HR: hazard ratio. 
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Table 2: efficacy results of phase 3, randomized, multicenter clinical trials in favor of high dose melphalan followed by autologous transplantation as upfront 
therapy in transplant eligible MM patients. 
STUDY N° OF PATIENTS 
TREATMEN
T SCHEME 
ORR (%) MEDIAN PFS (m) OS 
HDT-ASCT CC HDT-ASCT CC HDT-ASCT CC 
Attal et al59 204 
MEL140 + TBI 
(8 Gy) vs 
VMCP/BVAP 
→ IFN-α 
maintenance 
until relapse 
81 (CR 22) 57 (CR 5) 27* 18* Median OS: NR Median OS: 37 m 
Child et al61 407 
VCAM + 
MEL200 vs 
BCAM 
86 (CR 44) 48 (CR 8) 32 20 Median OS: 54 m Median OS: 42 m 
Palumbo et al89 302 
Rd → Tandem 
MEL200 vs 6 
MPR 
→ R 
maintenance 
until relapse 
93 (CR 23)† 91 (CR 18)† 43 22 4-year OS: 82% 4-year OS: 65% 
Gay et al104 389 
Rd → Tandem 
MEL200 vs 6 
CDR 
→ Rp 
maintenance 
until relapse 
91 (CR 13)† 89 (CR 12)† 43 29 4-year OS: 86% 4-year OS: 73% 
Cavo et alꭍ66 1503 
VCD → 
MEL200 vs  4 
VMP → 2 
VRD 
consolidation 
vs no 
consolidation 
→ R 
maintenance 
until relapse 
VGPR 84 VGPR 74 
PFS prolonged 
in HDT-ASCT 
arm (HR=0.76; 
95% CI=0.61-
0.94; P=0.010) 
NP NP 
16 
Attal et al67 707 
VRD → 
MEL200 + 2 
VRD vs 5 
VRD → R 
maintenance 
until relapse 
98 (CR 59) 97 (CR 48) 50 36 4-year OS: 81% 4-year OS: 82% 
 
Legend: ORR: overall response rate (≥PR); PR: partial response; CR: complete response; PFS: progression-free survival; m: months; OS: overall survival; HDT-
ASCT: high-dose chemotherapy followed by autologous stem cell transplant; CC: conventional chemotherapy; MEL140: melphalan 140 mg/m2 followed by 
ASCT; TBI: total body irradiation; MEL200: melphalan 200 mg/m2 followed by ASCT; VMCP: vincristine, melphalan, cyclophosphamide, prednisone; BVAP: 
vincristine, carmustine, doxorubicin, prednisone; *: in this trial survival parameter was event-free survival; NR: not reached; VCAM: vincristine, 
cyclophosphamide, doxorubicin, metil-prednisolone; BCAM: carmustine, cyclophosphamide, doxorubicin, melphalan; Rd: lenalidomide, dexamethasone; MPR: 
melphalan, prednisone, lenalidomide; †: results not significantly different; CDR: cyclophosphamide, dexamethasone, lenalidomide; Rp: lenalidomide,prednisone; 
ꭍ: interim analysis; VCD: bortezomib, cyclophosphamide, dexamethasone; VMP: bortezomib, melphalan, prednisone; VRD: bortezomib, lenalidomide, 
dexamethasone; VGPR: very good partial response; NP: not published; VRD: bortezomib, lenalidomide, dexamethasone. 
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Table 3: Melphalan associated FDA boxed warnings and related EBGMs 
Melphalan  
FDA approval 1 
Jan 1964 
Date ADR added Number of reports 
before a boxed warning  
Number of 
reports after a 
boxed warning 
EBGM before 
a boxed 
warning 
EBGM after a 
boxed warning 
First boxed 
warning 
16 June 1980 Leukemia 90 380 23.89 6.21 
First revision 22 September 1986 Chromosom
al 
aberrations 
0 46 0.00 13.19 
Second Revision 25 August 1994 Bone 
marrow 
suppression 
24 368 5.93 7.84 
Third Revision 14 May 2003  Hypersensit
ivity 
12 41 0.40 0.42 
Legend:  ADR: adverse event reaction, EBGM: Empirical Bayes Geometric Mean, 
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Drug Summary 
DRUG SUMMARY 
 
Drug name 
 
 
Melphalan (Alkeran ®, GlaxoSmithKline) 
 
Phase 
 
Oral formulation approved by FDA in 1964. On 2002 FDA approval of 
Alkeran® for injection. Currently in Phase IV (Post marketing surveillance) 
 
Indication 
 
Oral formulation: treatment of MM patients ineligible for ASCT. 
Intravenous HDM: preparative regimen for ASCT 
Pharmacology 
description 
 
Nitrogen mustard with a bi-functional non-specific alkylating activity towards 
DNA. IL-6 expression reduction in bone marrow environment. Immunogenic 
cell death. 
 
Route of administration 
 
Oral; Intravenous 
 
Chemical structure 
 
 
 
Pivotal trial(s) 
 
Alexanian et al 32; San Miguel et al 44; Fayers et al43;  Attal et al59;  Child et al61; 
Palumbo et al 89; 
 
 
Legend: MM: multiple myeloma, ASCT: autologous stem cell transplantation; HDM: high-dose-melphalan; 
IL-6: interleukin-6. 
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